India, Nov. 20 -- CytoSorbents Corporation (CTSO,HQE1.F) announced a $6.25 million common stock financing and a concurrent restructuring of its credit facility with Avenue Capital Group. The transactions are expected to reduce outstanding debt by $5.25 million, extend loan maturity by one year and lower future interest expenses. Shares were recently down 8.38%.

Registered Direct Offering

The financing includes approximately $4 million in gross cash proceeds through a registered direct offering priced at the market under Nasdaq rules. The offering includes common shares and pre-funded warrants, with approximately 75% subscribed by existing shareholders, management and members of the Board of Directors.

The company plans to use the net pro...